周五，Piper Sandler调整了对Omega Therapeutics (NASDAQ:OMGA)股票的展望，将目标价从此前的$9下调至$4，同时维持对该股票的增持评级。该公司的分析是基于Omega Therapeutics最近的财务和临床更新。 Omega Therapeutics在2024年第三季度结束时拥有3040万美元的现金储备，预计可以支持其运营至2025年第二季度。 该公司的MY ...

In a report released today, Edward Tenthoff from Piper Sandler maintained a Buy rating on Omega Therapeutics (OMGA – Research Report), ...

Raymond James downgraded Omega Therapeutics (OMGA) to Market Perform from Outperform. Published first on TheFly – the ultimate source ...

英为财情Investing.com - Omega Therapeutics (NASDAQ: OMGA )星期四发布了第三季度的财报，数据显示，公司营收高于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.300，总营收为$2.61M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$1.2M，每股收益为$-0.280.

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.40 per share a year ago.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

There are no important events for this country at this time. Select "All" to see top events in other countries or view all events.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Aug. 14, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today ...